PortfoliosLab logoPortfoliosLab logo
AUR vs. RXRX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

AUR vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Aurora Innovation, Inc. (AUR) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, AUR achieves a 101.04% return, which is significantly higher than RXRX's -11.74% return.


AUR

1D
3.35%
1M
25.94%
YTD
101.04%
6M
93.48%
1Y
31.74%
3Y*
75.02%
5Y*
-4.68%
10Y*

RXRX

1D
-4.75%
1M
6.49%
YTD
-11.74%
6M
-16.44%
1Y
-17.39%
3Y*
-24.02%
5Y*
-33.81%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

AUR vs. RXRX - Yearly Performance Comparison


2026 (YTD)20252024202320222021
AUR
Aurora Innovation, Inc.
101.04%-39.05%44.16%261.16%-89.25%12.60%
RXRX
Recursion Pharmaceuticals, Inc.
-11.74%-39.50%-31.44%27.89%-54.99%-25.65%

Correlation

The correlation between AUR and RXRX is 0.52, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.52

Correlation (3Y)
Calculated over the trailing 3-year period

0.44

Correlation (5Y)
Calculated over the trailing 5-year period

0.44

Correlation (All Time)
Calculated using the full available price history since May 11, 2021

0.43

The correlation between AUR and RXRX has been stable across timeframes, ranging from 0.43 to 0.52 - a consistent structural relationship.

Fundamentals

Market Cap

AUR:

$15.04B

RXRX:

$1.91B

EPS

AUR:

-$0.44

RXRX:

-$1.17

PS Ratio

AUR:

3.65K

RXRX:

26.15

PB Ratio

AUR:

7.66

RXRX:

1.86

Total Revenue (TTM)

AUR:

$4.00M

RXRX:

$66.29M

Gross Profit (TTM)

AUR:

$163.00M

RXRX:

-$22.83M

EBITDA (TTM)

AUR:

-$882.00M

RXRX:

-$505.90M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

AUR vs. RXRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AUR
AUR Risk / Return Rank: 5555
Overall Rank
AUR Sharpe Ratio Rank: 5858
Sharpe Ratio Rank
AUR Sortino Ratio Rank: 5858
Sortino Ratio Rank
AUR Omega Ratio Rank: 5454
Omega Ratio Rank
AUR Calmar Ratio Rank: 5555
Calmar Ratio Rank
AUR Martin Ratio Rank: 5252
Martin Ratio Rank

RXRX
RXRX Risk / Return Rank: 3232
Overall Rank
RXRX Sharpe Ratio Rank: 3131
Sharpe Ratio Rank
RXRX Sortino Ratio Rank: 3333
Sortino Ratio Rank
RXRX Omega Ratio Rank: 3232
Omega Ratio Rank
RXRX Calmar Ratio Rank: 3232
Calmar Ratio Rank
RXRX Martin Ratio Rank: 3333
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AUR vs. RXRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Aurora Innovation, Inc. (AUR) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


AURRXRXDifference

Sharpe ratio

Return per unit of total volatility

0.52

-0.24

+0.76

Sortino ratio

Return per unit of downside risk

1.21

0.16

+1.06

Omega ratio

Gain probability vs. loss probability

1.13

1.02

+0.12

Calmar ratio

Return relative to maximum drawdown

0.64

-0.23

+0.88

Martin ratio

Return relative to average drawdown

1.10

-0.39

+1.49

AUR vs. RXRX - Sharpe Ratio Comparison

The current AUR Sharpe Ratio is 0.52, which is higher than the RXRX Sharpe Ratio of -0.24. The chart below compares the historical Sharpe Ratios of AUR and RXRX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


AURRXRXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.52

-0.24

+0.76

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.05

-0.36

+0.31

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.06

-0.37

+0.31

Drawdowns

AUR vs. RXRX - Drawdown Comparison

The maximum AUR drawdown since its inception was -93.34%, roughly equal to the maximum RXRX drawdown of -93.13%. Use the drawdown chart below to compare losses from any high point for AUR and RXRX.


Loading charts...

Drawdown Indicators


AURRXRXDifference

Max Drawdown

Largest peak-to-trough decline

-93.34%

-93.13%

-0.21%

Max Drawdown (1Y)

Largest decline over 1 year

-42.53%

-58.17%

+15.64%

Max Drawdown (3Y)

Largest decline over 3 years

-63.00%

-82.09%

+19.09%

Max Drawdown (5Y)

Largest decline over 5 years

-93.34%

-93.13%

-0.21%

Current Drawdown

Current decline from peak

-54.88%

-91.27%

+36.39%

Average Drawdown

Average peak-to-trough decline

-67.47%

-75.33%

+7.86%

Ulcer Index

Depth and duration of drawdowns from previous peaks

24.91%

35.04%

-10.13%

Volatility

AUR vs. RXRX - Volatility Comparison

Aurora Innovation, Inc. (AUR) has a higher volatility of 23.30% compared to Recursion Pharmaceuticals, Inc. (RXRX) at 18.74%. This indicates that AUR's price experiences larger fluctuations and is considered to be riskier than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


AURRXRXDifference

Volatility (1M)

Calculated over the trailing 1-month period

23.30%

18.74%

+4.56%

Volatility (6M)

Calculated over the trailing 6-month period

48.80%

44.79%

+4.01%

Volatility (1Y)

Calculated over the trailing 1-year period

61.01%

73.46%

-12.45%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

90.48%

93.46%

-2.98%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

89.91%

93.62%

-3.71%

Dividends

AUR vs. RXRX - Dividend Comparison

Neither AUR nor RXRX has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

AUR vs. RXRX - Financials Comparison

This section allows you to compare key financial metrics between Aurora Innovation, Inc. and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0010.00M20.00M30.00M40.00M50.00M60.00M20222023202420252026
1.00M
6.47M
(AUR) Total Revenue
(RXRX) Total Revenue
Values in USD except per share items

Frequently Asked Questions


AUR and RXRX have a correlation of 0.52, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AUR has higher volatility (23.30%) compared to RXRX (18.74%). In terms of maximum drawdown, AUR dropped -93.34% vs RXRX's -93.13%.

AUR currently has the higher Sharpe Ratio (0.52 vs -0.24), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for AUR and RXRX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer